Lumexa Imaging Holdings Inc (LMRI) FinancialsLMRILumexa Imaging Holdings Inc

Lumexa Imaging Holdings, Inc. (LMRI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is OUTPATIENT, accounting for 74.4% of total sales, equivalent to $187.90M. Other significant revenue streams include PROFESSIONAL and INTERSEGMENT ELIMINATIONS. Understanding this composition is critical for investors evaluating how LMRI navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Lumexa Imaging Holdings, Inc. maintains a gross margin of 10.90%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 3.68%, while the net margin is 1.04%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively LMRI converts its operational activities into shareholder value.

In the context of the broader market, LMRI competes directly with industry leaders such as TDOC and OPK. With a market capitalization of $1.12B, it holds a significant position in the sector. When comparing efficiency, LMRI's gross margin of 10.90% stands against TDOC's 53.58% and OPK's 37.32%. Such benchmarking helps identify whether Lumexa Imaging Holdings, Inc. is trading at a premium or discount relative to its financial performance.

Lumexa reported Q2 revenue of $264.2 million, a 5.1% increase year-over-year, with a gross margin of 10.90%. The company has shown a turnaround with net income of $2.74 million in Q2 2026, compared to losses in previous quarters.